Vertex Pharmaceuticals Incorporated
Research & Development
About Vertex Pharmaceuticals Incorporated
The Science of Possibility.
Vertex Canada is home to innovators in biopharmaceutical research and development. We employ approximately 60 professionals at our research facility in Laval, Quebec, including approximately 45 scientists focused on drug discovery and development activities.
Vertex’s Canadian team is focused on research activities related to inflammatory bowel diseases (IBD), which include Crohn’s Disease and ulcerative colitis. Vertex Canada features a diverse scientific team covering all of our major disciplines and fosters strong cross-functional teams between departments.
Our workplace reflects the rich multiculturalism of the area, which our employees point to as a key advantage of working here. Scientists and researchers from our Laval location have strong collaborative relationships with academic institutions in the area, as well as with our other Vertex locations worldwide.
As part of Vertex’s global network of science research, the Laval site is positioned to continue its quarter century of Canadian contribution to discovering new possibilities in medicine and advancing Canada’s scientific research workforce.
For more information on Vertex, please visit www.vrtx.com. For information on career opportunities with Vertex Canada, please visit www.careers.vrtx.com/.
68 articles with Vertex Pharmaceuticals Incorporated
Vertex to Present New Data at European and North American Virtual Cystic Fibrosis Conferences Highlighting Long-Term Use of CFTR Modulators
Oral presentation of interim results from TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) open-label safety extension study to be presented at the ECFS Digital Conference
CRISPR Therapeutics and Vertex Announce New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies at the 25th Annual European Hematology Association (EHA) Congress
CRISPR Therapeutics and Vertex Pharmaceuticals Incorporated announced new clinical data for CTX001, an investigational CRISPR/Cas9 gene-editing therapy, from the CLIMB-111 and CLIMB-121 Phase 1/2 trials in transfusion-dependent beta thalassemia and severe sickle cell disease, and highlighted recent progress in the CTX001 development program.
Vertex Expands into New Disease Areas and Enhances Gene Editing Capabilities Through Expanded Collaboration with CRISPR Therapeutics and Acquisition of Exonics Therapeutics
Vertex Pharmaceuticals Incorporated announced that the company is enhancing its gene editing capabilities to develop novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1 by expanding its collaboration with CRISPR Therapeutics and acquiring Exonics Therapeutics.
Vertex to Present Data at ECFS Conference on Potential Impact of Early Treatment and Long-Term Treatment with CFTR Modulators on the Underlying Cause of CF
Vertex Pharmaceuticals Incorporated announced that data from six scientific abstracts from the company’s portfolio of cystic fibrosis medicines will be presented at the 42nd European Cystic Fibrosis Conference, taking place June 5-8, 2019 in Liverpool, UK.
Vertex Selects Triple Combination Regimen of VX-445, Tezacaftor and Ivacaftor to Submit for Global Regulatory Approvals in Cystic Fibrosis
Vertex Pharmaceuticals Incorporated announced that it has selected the triple combination of the next-generation corrector VX-445, tezacaftor and ivacaftor to submit for potential global regulatory approvals for people ages 12 and older with cystic fibrosis.
First-quarter 2019 product revenues of $857 million, a 34% increase compared to $638 million in 2018
Vertex Pharmaceuticals Incorporated will report its first quarter 2019 financial results on Tuesday, April 30, 2019 after the financial markets close.
Vertex Receives Approval for SYMDEKO® (tezacaftor/ivacaftor and ivacaftor) in Australia, to Treat the Underlying Cause of Cystic Fibrosis in People aged 12 and Older with Certain CFTR Gene Mutations
First medicine in Australia to treat the underlying cause of cystic fibrosis in patients who have certain mutations that result in residual CFTR function
Vertex Pharmaceuticals Incorporated announced that Lloyd Carney has been appointed to its board of directors as an independent director.
Vertex Pharmaceuticals Incorporated Reports Full-Year And Fourth Quarter 2014 Financial Results And Provides Guidance For 2015
Vertex Pharmaceuticals Incorporated Outlines 2015 Business Priorities To Support The Development, Approval And Launch Of New Medicines For The Treatment Of People With Cystic Fibrosis
Vertex Pharmaceuticals Incorporated Announces Upcoming Presentation At The J.P. Morgan Healthcare Conference And Date Of Fourth Quarter And Full Year 2014 Financial Results
Vertex Pharmaceuticals Incorporated To Present At The Credit Suisse Healthcare Conference On November 11
Vertex Pharmaceuticals Incorporated To Present At Morgan Stanley Global Healthcare Conference On September 10
Vertex Pharmaceuticals Incorporated Receives European Approval For KALYDECO (ivacaftor) In Eight Non-G551D Gating Mutations
Vertex Pharmaceuticals Incorporated Reports Second Quarter 2014 Financial Results And Provides Updates On Key Research And Development Programs